Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa